lifestyle.menstyle1.com

Author: RealChemistry/ BOEHRINGER INGELHEIM – oncology

Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England of Journal of Medicine

April 17, 2026
/C O R R E C T I O N — Boehringer Ingelheim/

April 16, 2026
Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England of Journal of Medicine

April 16, 2026